The FDA continues working to close cannabidiol data gaps while maintaining that CBD-containing cosmetics cannot be adulterated, misbranded or marketed as affecting body structure/function or treating or preventing disease, including skin ailments. Cosmetics office head Linda Katz revisited the issue during the Independent Beauty Association’s annual FDA Cosmetics Regulations Workshop.

The Executive Summary of an interagency working group's preliminary recommendations on testing methods for asbestos in talc and talc-containing consumer products, released by the FDA in early 2020, does not constitute a formal position taken by the FDA, it says, noting that concerns have arisen recently about misunderstanding among "external parties."

NGOs including the Environmental Working Group maintain that the FDA’s testing results released on 9 March, showing traces of asbestos in nine out of 52 talc-containing cosmetics, signal a need for congressional action to tighten industry oversight. The FDA says the findings are not necessarily representative of the overall marketplace, with further talc testing planned for 2020.